Results 41 to 50 of about 85,373 (307)
Molecular Oncology, EarlyView.We show that the majority of the 18 analyzed recurrent cancer‐associated ERBB4 mutations are transforming. The most potent mutations are activating, co‐operate with other ERBB receptors, and are sensitive to pan‐ERBB inhibitors. Activating ERBB4 mutations also promote therapy resistance in EGFR‐mutant lung cancer.
Veera K. Ojala +15 more
wiley +1 more source
Afrontamiento y calidad de vida en pacientes con cáncer de mama. [PDF]
, 2009 150 p.El diagnóstico de cáncer de mama es la tercera causa de muerte por cáncer en la mujer Chilena, y constituye una de las situaciones de mayor carga y estrés emocional para quienes lo padecen.
Escobar Ponce, Francisca Paz +1 more
core
Molecular Oncology, EarlyView.Aptamers are used both therapeutically and as targeting agents in cancer treatment. We developed an aptamer‐targeted PLGA–TRAIL nanosystem that exhibited superior therapeutic efficacy in NOD/SCID breast cancer models. This nanosystem represents a novel biotechnological drug candidate for suppressing resistance development in breast cancer.
Gulen Melike Demirbolat +8 more
wiley +1 more source
ANÁLISE ESPACIAL DA MORTALIDADE DO CÂNCER DE MAMA E COLO DE ÚTERO NO BRASIL EM 2004
Revista de Pesquisa Cuidado é Fundamental Online, 2009 No Brasil, o câncer de mama e do colo uterino tornou-se um grande problema de saúde pública em decorrência do elevado número de óbitos. Objetivo: Analisar a distribuição de óbitos por câncer de mama e colo uterino no Brasil. Métodos: Estudo descritivo de
Raíla Souza Santos +2 more
doaj +4 more sources
Revista Chilena de Obstetricia y Ginecología, 2022 En algunos estudios se ha asociado a la terapia de reemplazo hormonal (TRH) con estrógenos y progestinas a un mayor riesgo de cáncer de mama que la terapia con estrógenos solos.
Carla Bazán-Steffens +1 more
doaj +1 more source
"I am a complete woman" : dragon boat and breast cancer survival [PDF]
, 2017 Being diagnosed with breast cancer is like receiving a death sentence. While some surrender to their fate with diminished meaning of life, others manage to accept the challenges of their condition and move on with greater appreciation of life.
Guinto-Adviento, Maria Luisa +1 more
core +2 more sources
Targeting p38α in cancer: challenges, opportunities, and emerging strategies
Molecular Oncology, EarlyView.p38α normally regulates cellular stress responses and homeostasis and suppresses malignant transformation. In cancer, however, p38α is co‐opted to drive context‐dependent proliferation and dissemination. p38α also supports key functions in cells of the tumor microenvironment, including fibroblasts, myeloid cells, and T lymphocytes.
Angel R. Nebreda
wiley +1 more source
CANCER DE MAMA EN CHILE: DATOS EPIDEMIOLOGICOS
Revista chilena de obstetricia y ginecología, 2002 The epidemiological analysis of breast cancer in Chile is described. The experience in the San Borja Arriarán Hospital is presented where an improved rate of precocions diagnosis is noted.
openaire +3 more sources
COMP–PMEPA1 axis promotes epithelial‐to‐mesenchymal transition in breast cancer cells
Molecular Oncology, EarlyView.This study reveals that cartilage oligomeric matrix protein (COMP) promotes epithelial‐to‐mesenchymal transition (EMT) in breast cancer. We identify PMEPA1 (protein TMEPAI) as a novel COMP‐binding partner that mediates EMT via binding to the TSP domains of COMP, establishing the COMP–PMEPA1 axis as a key EMT driver in breast cancer.
Konstantinos S. Papadakos +6 more
wiley +1 more source
JCO Global OncologyPURPOSEIn 2013, Brazil implemented a federal law (Law 12.732/2012) mandating cancer treatment to begin within 60 days of diagnosis. Among women with newly diagnosed estrogen receptor–positive (ER+) nonmetastatic breast cancer, we describe the diagnosis ...
Romualdo Barroso-Sousa +20 more
doaj +1 more source